Associations between cardiovascular risk factors, hyper- and hypocoagulability
Rafi, S.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Chapter 8

The effect of haemophilia and von willebrand disease on arterial thrombosis: a systematic review

Sara Biere-Rafi, Marjan Zwiers, Marjolein Peters, Jan van der Meer, Frits R Rosendaal, Harry R Büller, Pieter W Kamphuisen

*Netherlands Journal of Medicine* 2010; 68: 207-14
ABSTRACT

Background Patients with haemophilia and von Willebrand disease (VWD) may have a reduced cardiovascular mortality, due to a hypocoagulable state or decreased atherogenesis. We performed a systematic review to assess the association between haemophilia and VWD, and fatal and nonfatal arterial thrombosis and asymptomatic atherosclerosis.

Methods Medline and PubMed were searched to identify studies that assessed the incidence of cardiovascular mortality and morbidity in haemophilia and VWD, and that measured asymptomatic atherosclerosis with intima media thickness (IMT) of the carotid and femoral arteries, or flow-mediated dilatation (FMD) of the brachial artery. Weighted standardised mortality ratios (SMR) and mean differences (WMD) were calculated and pooled using a random effects model.

Results 15 longitudinal and cross-sectional studies consisting of 19,242 patients were included. Mortality due to arterial thrombosis was nonsignificantly reduced in patients with haemophilia compared with healthy controls (SMR 0.51, 95% CI 0.24 to 1.09). Haemophilia reduced nonfatal coronary events, and severe haemophilia offered better protection, but these results were based on a single study. No results were available for VWD. Although IMT of the carotid and femoral arteries was similar between VWD and haemophilia patients and healthy controls, atherosclerotic plaques of the large arteries were less prevalent in haemophilia patients. Only two studies assessed FMD and the results were inconsistent.

Conclusion Haemophilia may reduce arterial thrombosis, but this association should be further studied in haemophilia patients with a higher prevalence of cardiovascular risk factors.
INTRODUCTION

The concept of risk factors in cardiovascular disease (CVD) has been well established. Smoking, hypertension, obesity, hypercholesterolemia, diabetes mellitus, and a positive family history for CVD are all associated with an increased risk of morbidity and mortality due to CVD. A prothrombotic state contributes to the development of CVD. Increased levels of fibrinogen, von Willebrand factor (VWF), and factor VIII have all been linked to arterial disease. VWF is essential for platelet adhesion and aggregation. Furthermore, VWF acts as the carrier protein for coagulation factor VIII. Factor VIII contributes to the formation of a fibrin-rich clot, and also has a role in the formation of occluding thrombi in stenotic vessels. Patients with haemophilia A, who have a congenital deficiency of clotting factor VIII, are thought to be protected against mortality due to arterial thrombosis. This protection may be due to hypocoagulability, which is associated with decreased thrombin generation and results in inhibition of thrombus formation.

On the other hand, haemophilia or VWD may also decrease the formation of atherosclerotic plaques. Studies evaluating preclinical atherosclerosis by measurement of intima media thickness (IMT) and flow mediated dilatation (FMD) are, however, conflicting. Moreover, autopsy findings have found extensive atherosclerotic plaques in subjects with von Willebrand disease (VWD) and haemophilia, and case reports have been published about patients with occlusive arterial thrombi.

Although this subject was recently reviewed, a systematic review assessing these studies has not been performed. We therefore systematically evaluated all literature to determine whether patients with haemophilia or VWD are protected against arterial thrombosis, and whether the prevalence of asymptomatic atherosclerosis is reduced. In order to thoroughly investigate this association, we first analyzed fatal arterial thrombosis, followed by non-fatal events, and finally we addressed preclinical atherosclerosis.

METHODS

Data sources and study selection

We identified all published studies that evaluated the prevalence of atherosclerosis and arterial thrombosis in patients or carriers with haemophilia A or B, and VWD. A comprehensive literature search was conducted by a clinical librarian of Medline from 1950 through December 2009, and Embase from 1980 through December 2009. The following search terms were used: haemophilia, von Willebrand disease or coagulation disorder. The results of this search were combined with a subsequent search, in which the terms were arterial thrombosis, cardiovascular disease, arterial occlusive disease, atherosclerosis, cerebral vascular accident, stroke, myocardial infarction, acute coronary event, peripheral vascular event, peripheral artery disease, intima media thickness and flow mediated dilation. No language restrictions were initially applied to the search. A manual
review of references from primary or review articles was performed to identify any additional relevant studies. The “related articles” feature of Pubmed was also used.

**Study selection**

Those studies that entailed observations of the same subjects over well-defined time periods were defined as longitudinal studies (e.g. prospective and retrospective cohort studies and registry studies). Longitudinal studies were included if they reported on mortality due to arterial thrombosis (i.e. ischemic heart disease or ischemic stroke) in carriers of haemophilia or patients with haemophilia or VWD. Carriers of haemophilia were also included in the analyses since they may have a bleeding tendency that can be similar to that of mild haemophiliacs. But, since the pooling of male haemophilia patients and female carriers may lead to heterogeneity, we analyzed these groups separately. We further specified that every longitudinal study should either report a standardized mortality ratio (SMR) with 95% confidence interval (95% CI) or report sufficient data to estimate this. To adjust for differences in age with the reference population, SMRs were calculated, in which the incidence rates in the patients and the general population are standardized with the age-distribution (in person-years) of the patients as weights. This leads to the calculation of an expected number of events, which is the number of events that would have happened in the patient group, if the population rates had applied to it. The SMR is the ratio of the observed over the expected number of events. Furthermore, all longitudinal studies reporting non-fatal arterial thrombotic events were also included. Only those cross-sectional studies that measured asymptomatic atherosclerotic disease in patients with haemophilia or VWD by means of ultrasonography, IMT or FMD were included in this review.

**Study selection and quality assessment**

After identifying relevant titles, the abstracts of these studies were read to decide if the study was eligible. The full article was retrieved when the information in the title or abstract appeared to meet the inclusion criteria of this systematic review. The list of articles was reviewed independently by two investigators (SB and MZ). Disagreement between the two reviewers was intended to be resolved by consensus or by the opinion of a third author if necessary. However, there was no disagreement during the review process.

Using a standardized data extraction sheet, the following data was collected from the articles: lead author, publication year, study design, sample size, years of follow-up, description of the study population, type of the coagulation disorder, and, if available, information on the classification of the coagulation disorders. In addition, the following baseline characteristics were extracted (if reported): mean age of the population and the number and proportion of male patients. From cross-sectional studies crude and adjusted (for cardiovascular risk factors) mean IMT thickness of carotid and femoral artery, and mean percent of flow mediated dilatation were extracted. From longitudinal studies the SMR for fatal and non-fatal arterial thrombotic events was either calculated or extracted. The quality of cohort studies was assessed using a specific checklist consistent with
the consensus recommendations by the Meta-analysis Of Observational Studies in Epidemiology group.\textsuperscript{17} Cohort studies were assessed for quality according to four design features for each study: prospective data collection, consecutive patient enrolment, a clearly stated duration of follow-up and a description of losses during follow-up.

**Statistical analysis**

Review Manager (RevMan version 5.0, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008) and the Stata statistical software package 10.0 (Stata Corp., College Station, TX) were used to pool data for each outcome variable. Summary estimates, including 95\% confidence intervals were calculated. The cross-sectional studies consisted of continuous outcome data, therefore means and standard deviations of IMT were used to calculate a weighted mean difference in the meta-analysis. Data was pooled using the random effect model, where appropriate. $X^2$-en I$^2$-statistics were used to assess between-study heterogeneity. The SMRs in the longitudinal studies were pooled using a random effects model and was added in a Poisson regression model by calculating the ratio of the number of observed over expected events, in which the number of observed events is the sum of the observed events in all studies, and the number of expected events is the sum of the expected number of events in all studies. Like for the SMRs of the individual studies, confidence intervals for the pooled SMR were based on a Poisson distribution of the observed number of events, whereas the expected number was considered invariant.

**RESULTS**

Our initial search yielded 4450 potential literature citations (Figure 1). Of these, 4349 were excluded after scanning titles. Eighty-six studies were excluded after reading the articles: 60 studies were case reports, 10 citations were letters, 3 were autopsy studies, 2 studies only reported venous thrombosis, another 2 were reviews, and in one study the SMR was not reported and could not be calculated. The interobserver agreement for study selection and quality assessment was 100\%. So, 15 studies were included in the present review, with a total number of 19,242 patients, with 14,754 haemophilia A patients, 3408 haemophilia B patients, 965 carriers of haemophilia A and B, and 115 VWD patients (Table 1).\textsuperscript{4-7,18-28} The number of patients in the various studies ranged from 24 to 6018. The mean age of the patients in the various studies varied between 35 and 54 years. Eight longitudinal studies\textsuperscript{22-26,28} and three cross-sectional studies\textsuperscript{6,18,19} investigated males. In the remaining three cross-sectional studies the percentage male subjects ranged between 43\% and 60\%.\textsuperscript{7,20,21} In the remaining longitudinal study all patients were female carriers."
Table 1. Characteristics of studies included in the systematic review

<table>
<thead>
<tr>
<th>Source</th>
<th>Total</th>
<th>Haemophilia A</th>
<th>Haemophilia B</th>
<th>Severe</th>
<th>Mild</th>
<th>Moderate</th>
<th>VWD</th>
<th>Design</th>
<th>Outcome</th>
<th>Follow-up</th>
<th>(n) loss to follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rosendaal et al (1989) 4</td>
<td>717</td>
<td>616</td>
<td>101</td>
<td>321</td>
<td>227</td>
<td>169</td>
<td>na</td>
<td>Longitudinal</td>
<td>Mortality</td>
<td>10.9</td>
<td>0</td>
</tr>
<tr>
<td>Koumbarelis et al (1994) 24</td>
<td>531</td>
<td>460</td>
<td>71</td>
<td>212</td>
<td>227</td>
<td>92</td>
<td>na</td>
<td>Longitudinal</td>
<td>Mortality</td>
<td>21</td>
<td>0</td>
</tr>
<tr>
<td>Bilora et al (1999) 20</td>
<td>76</td>
<td>64</td>
<td>na</td>
<td>nr</td>
<td>Nr</td>
<td>nr</td>
<td>22</td>
<td>Cross-sectional</td>
<td>IMT</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Soucie et al (2000) 25</td>
<td>2950</td>
<td>2334</td>
<td>616</td>
<td>1252</td>
<td>902</td>
<td>717</td>
<td>na</td>
<td>Longitudinal</td>
<td>Mortality</td>
<td>2.6</td>
<td>71</td>
</tr>
<tr>
<td>Sramek et al (2002) 16</td>
<td>76</td>
<td>52</td>
<td>7</td>
<td>20</td>
<td>34</td>
<td>5</td>
<td>17</td>
<td>Cross-sectional</td>
<td>IMT</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Bilora et al (2001) 9</td>
<td>40</td>
<td>25</td>
<td>na</td>
<td>nr</td>
<td>Nr</td>
<td>nr</td>
<td>15</td>
<td>Cross-sectional</td>
<td>IMT</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Sramek et al (2003) 27</td>
<td>965</td>
<td>#</td>
<td>nr</td>
<td>nr</td>
<td>Nr</td>
<td>nr</td>
<td>na</td>
<td>Longitudinal</td>
<td>Mortality</td>
<td>15</td>
<td>33</td>
</tr>
<tr>
<td>Kulkarni et al (2005) 16</td>
<td>3422</td>
<td>2714</td>
<td>708</td>
<td>1419</td>
<td>1083</td>
<td>827</td>
<td>na</td>
<td>Longitudinal</td>
<td>Arterial events</td>
<td>6</td>
<td>nr</td>
</tr>
<tr>
<td>Darby et al (2007) 5</td>
<td>6018</td>
<td>4874</td>
<td>1144</td>
<td>3222</td>
<td>1320</td>
<td>1476</td>
<td>-</td>
<td>Longitudinal</td>
<td>Mortality</td>
<td>21</td>
<td>194</td>
</tr>
<tr>
<td>Sartori et al (2008) 19</td>
<td>40</td>
<td>38</td>
<td>2</td>
<td>nr</td>
<td>Nr</td>
<td>nr</td>
<td>-</td>
<td>Cross-sectional</td>
<td>IMT, FMD</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total</td>
<td>19242</td>
<td>14754</td>
<td>3408</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>115</td>
<td></td>
</tr>
</tbody>
</table>
Cardiovascular mortality in patients with hemophilia

All longitudinal studies described cause specific mortality. All studies reported on both haemophilia A and B patients, but the influence of the type of hemophilia was not analyzed separately. One of these studies, by Šrámek and colleagues, studied carriers of haemophilia A and B. None of the longitudinal studies analyzed patients with VWD. The duration of follow-up varied between 2 and 21 years. Follow-up was complete in 2 studies, and nearly complete (lost to follow up <5%) in 6 other studies. Information on various parameters in the longitudinal studies was mostly obtained through surveys supplemented with data from the haemophilia treatment centers, treating or attending physicians, municipal registries and death certificates. All studies compared cause specific mortality with that of the general male population obtained through either the Central Bureau of Statistics or the World Health Organization.

Most longitudinal studies assessed cardiovascular mortality due to ischemic heart disease, whereas one study also mentioned mortality due to ischemic stroke. One longitudinal study reported on mortality due to circulatory disease without further specifying the underlying causes, and was therefore left out from the pooled analysis. Three longitudinal studies assessed Dutch haemophilia patients from 1976 to 2001.

The mean age of mortality in the various studies ranged between 44 and 54 years. Overall, the number of fatal arterial thrombotic events was low. Compared to the general population, patients with haemophilia had a non-significant reduced mortality due to arterial thrombosis. For the seven studies, the overall SMR using a random effect model was 0.51 (95% CI 0.24-1.09). There was considerable, but not significant, heterogeneity between the studies (p=0.12) (Figure 2). All longitudinal studies, with the exception of the study by Soucie and colleagues, found a reduced mortality due to arterial thrombosis in carriers and patients with haemophilia,

Figure 1. Flow chart

4450 citations identified and screened
4349 excluded after title and abstract screening
101 retrieved for more detailed evaluation
86 articles excluded
  60 case reports
  10 letters
  6 venous disease
  4 other reasons
  3 autopsy studies
  2 reviews
  1 no comparable data
15 studies included in the systematic review
but due to the low number of events, confidence intervals were wide. Exclusion of the study with haemophilia carriers resulted in a SMR of 0.59 (0.33-1.05). When restricting analyses to studies with a follow-up period of 10 years or longer and that had complete follow-up, the association between a lower cardiovascular mortality and haemophilia became more consistent (overall SMR 0.59, 0.48-0.72). In the only study that investigated the influence of haemophilia on ischemic stroke, the SMR was 0.63, with a wide confidence interval (0.17-1.62). The influence of the severity of haemophilia on cardiovascular mortality was assessed in one study, by Darby and colleagues. A similar reduction in cardiovascular mortality was found in patients with severe, moderate and mild haemophilia, but, again, the number of fatal cardiovascular events was too low to detect potential differences (1.2% in patients with severe haemophilia, and 1.9% for patients with moderate and mild haemophilia).

### Non-fatal cardiovascular disease

Only one study investigated the influence of haemophilia on non-fatal arterial thrombotic events. The occurrence of ischemic heart disease (consisting of acute myocardial infarction, acute/subacute coronary syndrome, angina pectoris, and chronic heart disease) in 3422 patients with haemophilia was based on hospital discharge diagnosis, and was compared with general U.S. males based on the National Hospital Discharge survey. From 1993 till 1998, ischemic heart disease was reported 79 times in 48 patients, corresponding with a prevalence of approximately 2.3%. Among 45- to 64-year old haemophilic men, the discharge rate (per 1000) of ischemic heart disease was 24.1, 50% lower compared to that of U.S males (48.9/1000). This difference was 28% among patients of 64 years and older (127.3 versus 175.6 respectively). In addition, the
incidence of IHD was higher in patients with mild haemophilia (3.4%) than in moderate-severe (0.7%) or severe (0.4%) type of haemophilia (p<0.001). When haemophilia A and B was analyzed separately, IHD was more prevalent in patients with haemophilia B (2.4%) than haemophilia A (1.1%) (p<0.05). No studies assessed the prevalence of peripheral arterial disease or stroke.

Prevalence of asymptomatic atherosclerosis in haemophilia and VWD

Of the 6 cross-sectional studies 6,7,18-21 that assessed endothelial function or preclinical atherosclerotic disease, one study 19 involved patients with haemophilia A and B, two studies 6,20 involved patients with haemophilia A and VWD, one study haemophilia A and B and VWD18, whereas one study 21 described patients with type IIb VWD, and one study 7 investigated type 3 VWD patients. None of the studies was performed on either the same or an overlapping patient group. The ultrasonographers were not blinded for the severity of the bleeding disorder in any of the studies.

Intima Media Thickness

Four studies assessed the presence of asymptomatic atherosclerosis by measuring IMT of the carotid artery, 7,18,19,21 with a total of 187 patients (99 haemophilia patients and 88 patients with VWD) and 290 control subjects, whereas three studies also assessed the femoral artery. 7,19,21 Overall, the mean IMT of the carotid artery was 0.75 mm in patients with haemophilia and VWD and 0.74 mm in healthy controls, matched for age and sex (WMD 0.01 mm, 95% CI -0.02-0.04). The mean IMT of the femoral artery was 0.75 mm in patients with a coagulation disorder and 0.79 mm in controls (WMD -0.04 mm, 95% CI -0.10-0.02). Statistical heterogeneity was not present in either of the two analyses.

Figure 3a. Carotid IMT in patients with haemophilia and VWD compared to healthy controls

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IV, Random, 95% CI</td>
<td>IV, Random, 95% CI</td>
</tr>
<tr>
<td>Bilora et al 2007</td>
<td>0.01 [-0.16, 0.18]</td>
<td>0.00 [-0.05, 0.05]</td>
</tr>
<tr>
<td>Sartori et al 2008</td>
<td>0.04 [-0.02, 0.10]</td>
<td>-0.01 [-0.06, 0.04]</td>
</tr>
<tr>
<td>Sramek et al 2001</td>
<td>0.00 [-0.08, 0.04]</td>
<td>0.00 [-0.05, 0.05]</td>
</tr>
<tr>
<td>Sramek et al 2004</td>
<td>0.06 [-0.09, 0.11]</td>
<td>0.05 [-0.01, 0.06]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>0.01 [-0.02, 0.04]</td>
<td>0.00 [-0.03, 0.05]</td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.00; Chi² = 1.80, df = 3 (P = 0.61); I² = 0%
Test for overall effect: Z = 0.51 (P = 0.61)

Figure 3b. Femoral IMT in patients with haemophilia and VWD compared to healthy controls

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IV, Random, 95% CI</td>
<td>IV, Random, 95% CI</td>
</tr>
<tr>
<td>Bilora et al 2007</td>
<td>0.04 [-0.17, 0.09]</td>
<td>0.03 [-0.00, 0.06]</td>
</tr>
<tr>
<td>Sramek et al 2001</td>
<td>0.08 [-0.17, 0.01]</td>
<td>0.08 [-0.00, 0.16]</td>
</tr>
<tr>
<td>Sramek et al 2004</td>
<td>0.02 [-0.08, 0.12]</td>
<td>0.02 [-0.04, 0.10]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>0.01 [-0.04, 0.02]</td>
<td>0.00 [-0.08, 0.07]</td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.00; Chi² = 2.19, df = 2 (P = 0.33); I² = 9%
Test for overall effect: Z = 1.22 (P = 0.22)
The presence of atherosclerotic lesions and extent of the occlusion of the arteries was assessed by ultrasonography in two studies, without quantification of the IMT. The presence of atherosclerotic plaques was analyzed in various arteries (common carotid, bifurcation, brachial, femoral and abdominal aorta) of patients with haemophilia A or VWD. In the first study, atherosclerotic plaques of the carotid artery were present in 13.1% of 76 patients with haemophilia A and VWD (mean age 58 years), and in 27.2% of the 77 controls (p<0.05). This difference was more pronounced in patients older than 60 years. In the second study, atherosclerotic plaques in the abdominal aorta were present in 7.5% of the 40 patients with haemophilia A and VWD (mean age 48 years) and in 27.5% of the 40 controls (p<0.001). Twelve and a half percent of the 40 patients and 42.5% of the 40 control subjects had plaques in the leg arteries (p<0.001).

Four cross-sectional studies analysed the relation between the severity of the coagulation defect and atherosclerosis. In the study by Šrámek and colleagues mean IMT of the femoral arteries was similar in patients with moderate and severe haemophilia (0.74 mm, 95% CI 0.64-0.87) and in individuals with a mild form (0.76 mm, 95% CI 0.69-0.84). Also in the study by Sartori and colleagues, IMT of the carotid artery was not different between patients with moderate to severe compared mild haemophilia. Two studies by Bilora et al. showed less atherosclerotic plaques in patients with a more severe coagulation defect.

**Flow Mediated Dilatation**

Endothelial dysfunction, assessed with FMD, was analyzed in two studies. FMD was lower in 40 haemophilia patients compared to 40 controls (3.8 ± 5.2% vs. 20.3 ± 13.0%, P < 0.0001) in the first study, and this difference remained after adjustment for viral infections. In this study, severity of haemophilia did not affect FMD. In the second study, the percentage of vasodilation was 15.2 ± 3.1% in 24 type IIb VWD patients and 14.1 ± 2.9% in 24 controls, which was not different.

**DISCUSSION**

Our findings suggest that mortality due to ischemic heart disease is 50% lower in patients with haemophilia when compared to the general population. This association is more consistent in studies with longer and complete follow-up. Asymptomatic atherosclerosis as measured by IMT of the carotid and femoral arteries in patients with VWD and haemophilia was not different from healthy matched controls, but atherosclerotic plaques of the large arteries were less prevalent in these patients. Interestingly, in the only (large) study assessing non-fatal cardiovascular events, haemophilia not only reduced cardiovascular events, but patients with severe haemophilia had fewer events than those with mild or moderate haemophilia. Haemophilia B patients had more cardiovascular events than those with type A. The influence of VWD on cardiovascular events has not been studied.
The potential beneficial effect of haemophilia on arterial thrombosis could be the result of reduced thrombin formation. Thrombin is the key player in both fibrin formation and platelet activation. Thrombin cleaves fibrinogen to form fibrin, but can also trigger platelet activation through Protease-Activated Receptors (PAR) 1 and 4. This may lead to the formation of thrombi and ultimately to vascular occlusion. Importantly, thrombin may also influence the process of atherosclerosis. Tissue factor and PARs are highly expressed in human atheroma and are induced in response to injury in animal models. In vitro, PAR activation induces leucocyte chemotaxis, smooth muscle cell proliferation and migration, which may lead to arterial remodeling and stenosis of the injured artery. In addition, coagulation factors and PARs are also involved in inflammatory responses and repair after injury. These data suggest that local arterial damage may trigger both platelet activation and thrombin formation, which may further lead to arterial remodeling. It may well be that patients with haemophilia, who have a decreased thrombin formation, are relatively protected from these atherosclerotic processes.

Our systematic review cannot answer the question whether the association between haemophilia and arterial thrombosis is causal. The observed reduction in mortality, for instance, could be explained by a difference in cardiovascular risk factors between individuals with and without haemophilia. As previously shown by Rosendaal and colleagues, this seems not to be an explanation. As a prerequisite for causality, the association between haemophilia and arterial thrombosis seems biologically plausible. In addition, the association was consistent in different studies; only the study by Soucie and colleagues found no reduction in cardiovascular mortality. Furthermore, there seemed to be a dose-response gradient, in the sense that a more severe deficiency of factor VIII offered better protection. Although this was not apparent in two longitudinal studies, a more severe type of haemophilia also seemed to reduce non-fatal events and atherosclerotic plaques compared to mild haemophilia. However, these data were based on a small number of patients and events, affecting the strength of the association. Finally, also carriers of haemophilia had a 36% reduction in mortality due to ischemic heart disease.

Life-long hypocoagulability may be an interesting model to investigate the role of haemostasis in the occurrence of arterial thrombosis and the formation of atherosclerotic plaques. Further studies on this subject could serve two goals. First, the role of coagulation in the formation of atherosclerotic plaque formation could be further explored. If low factor VIII levels reduce atherogenesis and this is mediated through decreased thrombin generation, specific anticoagulants, like thrombin inhibitors, may be beneficial. Next, if patients with haemophilia and cardiovascular risk factors are not protected against atherosclerosis, cardiovascular prevention will also be applicable to haemophilia patients, since the life expectancy of these patients has considerably increased.

However, we noticed some methodological drawbacks of the studies included in this systematic review. In general, the number of fatal cardiovascular events was low, mostly due to the relatively young age of the patients, and therefore confidence intervals were wide. Non-fatal cardiovascular events, which are more prevalent than fatal ones, were reported only in one longitudinal study. Furthermore, the low life-expectancy of haemophilia patients as a result of bleeding complications
and poor treatment regimens in the 70s and 80s of the last century may have affected cause specific mortality ratios. Also HIV, a well-known cardiovascular risk factor, may have influenced cardiovascular mortality, but was seldom mentioned in the studies. However, Darby and colleagues showed a 40% reduction in cardiovascular mortality in haemophilia patients without HIV. Also in the IMT studies, the number of participants was small, whereas the detection of significant differences in IMT requires large populations. Together with the relative young age of the participants and a low prevalence of cardiovascular risk factors, an inverse association between hypocoagulability and atherosclerosis is difficult to detect. Since IMT is clearly affected by age and atherosclerotic risk factors, the question whether a hypocoagulable state protects against atherosclerosis should be studied in older patients with a higher prevalence of cardiovascular risk factors.

In conclusion, this systematic review suggests that patients with haemophilia have a reduced cardiovascular mortality. Whether this reduction is mediated by a lesser formation of atherosclerosis should be investigated in patients with a higher prevalence of cardiovascular risk factors.
REFERENCES


